Chemoprevention of head and neck cancer

Current Oncology Reports

Volumn 5, Issue 2, 2003, Pages 152-157

  Glover, Katrina Y ^b   Papadimitrakopoulou, Vali A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; BETA CAROTENE; BOWMAN BIRK INHIBITOR; CYCLIN DEPENDENT KINASE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ETRETINATE; FENRETINIDE; GREEN TEA EXTRACT; INDOMETACIN; ISOFLAVONE DERIVATIVE; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTIC ACID; POLYPHENOL DERIVATIVE; PROTEINASE INHIBITOR; RETINOL; SAPONIN DERIVATIVE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER RISK; CARCINOGENESIS; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG MEGADOSE; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; LARYNX CARCINOMA; LEUKOPLAKIA; LOW DRUG DOSE; PROTO ONCOGENE; REVIEW; RISK FACTOR; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; GENETICS; HEAD AND NECK TUMOR; METHODOLOGY;

ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 0142196853     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0103-x     Document Type: Review

References (55)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
2. Mashberg A: Re: Oral cavity cancer in non-users of tobacco. J Natl Cancer Inst 1993, 85:1525.
3. Vokes EE, Weichselbaum RR, Lippman SM, et al.: Head and neck cancer. N Engl J Med 1993, 328:184-194.
4. Cooper JS, Pajak TF, Rubin P, et al.: Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989. 17:449-456.
5. Lippman SM, Spitz M, Trizna Z, et al.: Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer 1994, 74(Suppl):2719-2725.
6. Jones AS, Morar P, Phillips DE, et al.: Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995, 75:1343-1353.
7. Lippman SM, Hong WK: Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989, 17:691-694.
8. Sporn MB, Dunlop NM, Newton, DL, Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35:1332-1338.
9. Hong WK, Sporn MB: Recent advances in chemoprevention of cancer. Science 1997, 278:1073-1077.
10. Rothman KJ, Cann CI, Flanders D, Fried MP: Epidemiology of laryngeal cancer. Epidemiol Rev 1980, 2:195-209.
11. Tuyns AJ, Esteve J, Raymond C: Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer 1988, 41:483-491.
12. De Stefani E, Correa P, Oreggia F, et al.: Risk factors for laryngeal cancer. Cancer 1987, 60:3087-3091.
13. Saracci R: The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol Rev 1987, 9:175-193.
14. Shields PC, Harris CC: Molecular epidemiology and the genetics of environmental cancer. JAMA 1991, 266:681-687.
15. Hsu TC, Cherry LM, Samaan NA: Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet Cytogenet 1985, 17:307-313.
16. Spitz MR, Fueger JJ, Beddingfield NA, et al.: Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 1989, 49:4626-4628.
17. Spitz MR, Hogue A, Trizna Z, et al.: Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomark Prev 1993, 2:329-333.
18. Knudson AG Jr, Hethcote HW, Brown BW: Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975, 72:5116-5120.
19. Lee JS, Kim S, Hong WK, et al.: Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 1993, 85:1951-1954.
20. Voravud N, Shin DM, KO JY, et al.: Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res 1993, 53:2874-2883.
21. Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med 2001, 345:1890-1900.
22. Brennan JA, Boyle JO, Koch WM, et al.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995, 332:712-717.
23. Grandis R, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993, 53:3579-3584.
24. Grandis JR, Tweardy DJ, Melhem MF: Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998, 4:13-20.
25. Shin DM Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994, 54:3153-3159.
26. Mao L, Lee JS, Fan YH, et al.: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996, 2:682-685.
27. Partridge M, Pateromichelaki SS, Phillips E, et al.: A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000, 60:3893-3898.
28. Rosin MP, Cheng X, Poh C, et al.: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000, 6:357-362.
29. van der Riet P, Nawroz H, Hruban RH, et al.: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994, 54:1156-1158.
30. Califano J, Westra WH, Meininger G, et al.: Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000, 6:347-352.
31. Guo Z, Yamaguchi K, Sanchez-Cespedes M, et al.: Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res 2001, 7:1963-1968.
32. Sanchez-Cespedes M, Esteller M, Wu L, et al.: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000, 60:892-895.
33. Hong WK, Endicott J, Itri LM, et al.: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315:1501-1505.
34. Lippman SM, Batsakis JG, Toth BB, et al.: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993, 328:15-20.
35. Stich HF, Hornby AP, Mathew B, et al.: Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988, 40:93-101.
36. Han J, Jiao L, Lu Y, et al.: Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 1990, 4:153-160.
37. Chiesa E, Tradati N, Merazza M, et al.: Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem 1993, 17F (Suppl):255-261.
38. Agarwal R, Mukhdtar H: Cancer chemoprevention by polyphenols in green tea and artichoke. Adv Exp Med Biol 1996, 401:35-50.
39. Schantz SP, Ostroff JS: Novel approaches to the prevention of head and neck cancer. Proc Soc Exp Biol Med 1997, 216:275-282.
40. Blot WJ, Chow WH, McLaughlin JK: Tea and cancer: a review of the epidemiological evidence. Eur J Cancer Prev 1996, 5:425-438.
41. Yang CS, Wang ZY: Tea and cancer. J Natl Cancer Inst 1993, 85:1038-1049.
42. Stich HF: Teas and tea components as inhibitors of carcinogen formation in model systems and man. Prev Med 1992, 21:377-384.
43. Panje WR: Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981, 107:658-663.
44. Chan G, Boyle JO, Yang EK, et al.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:991-994.
45. Messina M, Barnes S: The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991, 83:541-546.
46. Messina MJ, Persky V, Setchell KD, Barnes S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994, 21:113-131.
47. Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998, 78:167-209.
48. Fournier DB, Erdman JW, Gordon GB: Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomark Prev 1998, 7:1055-1065.
49. Kennedy AR, Manzone H: Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. J Cell Biochem 1995, 22 (Suppl):188-194.
50. Armstrong WB, Kennedy AR, Wan XS, et al.: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomark Prev 2000, 9:43-47.
51. Papadimitrakopoulou VA, Clayman GL, Shin DM, et al.: Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999, 125:1083-1089.
52. Shin DM, Khuri FR, Murphy B: Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001, 19:3010-3017.
53. Hong WK, Lippman SM, Itri LM, et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990, 323:795-801.
54. Bolla M, Lefur R, Ton Van J, et al.: Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx: results of a multicentric double-blind randomised study. Eur J Cancer 1994, 30A:767-772.
55. Khuri FR, Kim ES, Lee JJ, et al.: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomark Prev 2001, 10:823-829.